Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells

Other literature type, Article English OPEN
Brambilla, Riccardo ; Biffi, A. ; Bordignon, C. ; Naldini, L. (2004)
  • Publisher: American Society for Clinical Investigation
  • Related identifiers: doi: 10.1172/JCI200419205
  • Subject: Hematopoietic Stem Cell Transplantation | Gene Therapy | Article

Gene-based delivery can establish a sustained supply of therapeutic proteins within the nervous system. For diseases characterized by extensive CNS and peripheral nervous system (PNS) involvement, widespread distribution of the exogenous gene may be required, a challenge to in vivo gene transfer strategies. Here, using lentiviral vectors (LVs), we efficiently transduced hematopoietic stem cells (HSCs) ex vivo and evaluated the potential of their progeny to target therapeutic genes to the CNS and PNS of transplanted mice and correct a neurodegenerative disorder, metachromatic leukodystrophy (MLD). We proved extensive repopulation of CNS microglia and PNS endoneurial macrophages by transgene-expressing cells. Intriguingly, recruitment of these HSC-derived cells was faster and more robust in MLD mice. By transplanting HSCs transduced with the arylsulfatase A gene, we fully reconstituted enzyme activity in the hematopoietic system of MLD mice and prevented the development of motor conduction impairment, learning and coordination deficits, and neuropathological abnormalities typical of the disease. Remarkably, ex vivo gene therapy had a significantly higher therapeutic impact than WT HSC transplantation, indicating a critical role for enzyme overexpression in the HSC progeny. These results indicate that transplantation of LV-transduced autologous HSCs represents a potentially efficacious therapeutic strategy for MLD and possibly other neurodegenerative disorders.
  • References (48)
    48 references, page 1 of 5

    1. Kolodney, E.H., and Fluharty, A.L. 1995. Metachromatic leukodystrophy and multiple sulfatase deficiency: sulfatide lipidosis. In The metabolic and molecular bases of inherited disease. 6th edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill, New York, USA. 2693-7391.

    2. Neufeld, E.F. 1991. Lysosomal disease. Annu. Rev. Biochem. 60:257-280.

    3. Kay, M.A., Glorioso, J.C., and Naldini, L. 2001. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7:33-40.

    4. Glorioso, J.C., Mata, M., and Fink, D.J. 2003. Therapeutic gene transfer to the nervous system using viral vectors. J. Neurovirol. 9:165-172.

    5. Consiglio, A., et al. 2001. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 7:310-316.

    6. Bosch, A., Perret, E., Desmaris, N., Trono, D., and Heard, J.M. 2000. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11:1139-1150.

    7. Kordower, J.H., et al. 1999. Lentiviral gene transfer to the nonhuman primate brain. Exp. Neurol. 160:1-16.

    8. Taylor, R.M., and Wolfe, J.H. 1997. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat. Med. 3:771-774.

    9. Bachoud-Levi, A.C., et al. 2000. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum. Gene Ther. 11:1723-1729.

    10. Hickey, W.F., Vass, K., and Lassmann, H. 1992. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J. Neuropathol. Exp. Neurol. 51:246-256.

  • Metrics
    No metrics available
Share - Bookmark